Compile Data Set for Download or QSAR
Report error Found 45 Enz. Inhib. hit(s) with all data for entry = 11297
LigandPNGBDBM605238(US11673876, Comparative Compound 1)
Affinity DataIC50: 2nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Mekanistic Therapeutics

US Patent
LigandPNGBDBM605238(US11673876, Comparative Compound 1)
Affinity DataIC50: 2nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

LigandPNGBDBM605270(US11673876, Comparative Compound 2)
Affinity DataIC50: 2nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Mekanistic Therapeutics

US Patent
LigandPNGBDBM605270(US11673876, Comparative Compound 2)
Affinity DataIC50: 2nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

LigandPNGBDBM605450(N-(2-chloro-5-(3-cyano-4-((1-(4- fluorophenyl)ethy...)
Affinity DataIC50: 2nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Mekanistic Therapeutics

US Patent
LigandPNGBDBM605452(N-(2-chloro-5-(4-((1S-(4- fluorophenyl)ethyl)amino...)
Affinity DataIC50: 2nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Mekanistic Therapeutics

US Patent
LigandPNGBDBM605450(N-(2-chloro-5-(3-cyano-4-((1-(4- fluorophenyl)ethy...)
Affinity DataIC50: 2nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

LigandPNGBDBM605443(N-(2-chloro-5-(3-cyano-4-((1S- phenylethyl)amino)q...)
Affinity DataIC50: 2nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

LigandPNGBDBM605452(N-(2-chloro-5-(4-((1S-(4- fluorophenyl)ethyl)amino...)
Affinity DataIC50: 2nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

LigandPNGBDBM605440(N-(2-chloro-5-(4-((1S- phenylethyl)amino)quinazoli...)
Affinity DataIC50: 2nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Mekanistic Therapeutics

US Patent
LigandPNGBDBM605443(N-(2-chloro-5-(3-cyano-4-((1S- phenylethyl)amino)q...)
Affinity DataIC50: 2nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Mekanistic Therapeutics

US Patent
LigandPNGBDBM605440(N-(2-chloro-5-(4-((1S- phenylethyl)amino)quinazoli...)
Affinity DataIC50: 2nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Mekanistic Therapeutics

US Patent
LigandPNGBDBM605442(N-(2-chloro-5-(3-cyano-4-((1R- phenylethyl)amino)q...)
Affinity DataIC50: 11nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Mekanistic Therapeutics

US Patent
LigandPNGBDBM605449(4-((1-phenylethyl)amino)-6-(1H- pyrazolo[3,4-b]pyr...)
Affinity DataIC50: 11nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Mekanistic Therapeutics

US Patent
LigandPNGBDBM605444(6-(2-aminopyrimidin-5-yl)-4-((1- phenylethyl)amino...)
Affinity DataIC50: 11nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

LigandPNGBDBM605451(N-(2-chloro-5-(4-((1R-(4- fluorophenyl)ethyl)amino...)
Affinity DataIC50: 11nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Mekanistic Therapeutics

US Patent
LigandPNGBDBM605445((R)-6-(2-aminopyrimidin-5-yl)-4-((1- phenylethyl)a...)
Affinity DataIC50: 11nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Mekanistic Therapeutics

US Patent
LigandPNGBDBM605449(4-((1-phenylethyl)amino)-6-(1H- pyrazolo[3,4-b]pyr...)
Affinity DataIC50: 11nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

LigandPNGBDBM605442(N-(2-chloro-5-(3-cyano-4-((1R- phenylethyl)amino)q...)
Affinity DataIC50: 11nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Mekanistic Therapeutics

US Patent
LigandPNGBDBM605441(6-(5,6-dimethoxypyridin-3-yl)-N-(1- phenylethyl)qu...)
Affinity DataIC50: 11nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Mekanistic Therapeutics

US Patent
LigandPNGBDBM605453(6-(2-aminopyrimidin-5-yl)-N-(1-(4- fluorophenyl)et...)
Affinity DataIC50: 11nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Mekanistic Therapeutics

US Patent
LigandPNGBDBM605439(N-(2-chloro-5-(4-((1R- phenylethyl)amino)quinazoli...)
Affinity DataIC50: 11nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Mekanistic Therapeutics

US Patent
LigandPNGBDBM605439(N-(2-chloro-5-(4-((1R- phenylethyl)amino)quinazoli...)
Affinity DataIC50: 11nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

LigandPNGBDBM605439(N-(2-chloro-5-(4-((1R- phenylethyl)amino)quinazoli...)
Affinity DataIC50: 11nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Mekanistic Therapeutics

US Patent
LigandPNGBDBM605454(6-(5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol- 2-yl)pyri...)
Affinity DataIC50: 11nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Mekanistic Therapeutics

US Patent
LigandPNGBDBM605454(6-(5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol- 2-yl)pyri...)
Affinity DataIC50: 11nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Mekanistic Therapeutics

US Patent
LigandPNGBDBM605270(US11673876, Comparative Compound 2)
Affinity DataIC50: 11nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

LigandPNGBDBM605454(6-(5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol- 2-yl)pyri...)
Affinity DataIC50: 110nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Mekanistic Therapeutics

US Patent
LigandPNGBDBM605451(N-(2-chloro-5-(4-((1R-(4- fluorophenyl)ethyl)amino...)
Affinity DataIC50: 110nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Mekanistic Therapeutics

US Patent
LigandPNGBDBM605238(US11673876, Comparative Compound 1)
Affinity DataIC50: 110nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Mekanistic Therapeutics

US Patent
LigandPNGBDBM605445((R)-6-(2-aminopyrimidin-5-yl)-4-((1- phenylethyl)a...)
Affinity DataIC50: 110nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Mekanistic Therapeutics

US Patent
LigandPNGBDBM605444(6-(2-aminopyrimidin-5-yl)-4-((1- phenylethyl)amino...)
Affinity DataIC50: 110nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

LigandPNGBDBM605441(6-(5,6-dimethoxypyridin-3-yl)-N-(1- phenylethyl)qu...)
Affinity DataIC50: 110nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Mekanistic Therapeutics

US Patent
LigandPNGBDBM605438(US11673876, Comparative Compound 3)
Affinity DataIC50: 110nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

LigandPNGBDBM605438(US11673876, Comparative Compound 3)
Affinity DataIC50: 110nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

LigandPNGBDBM605449(4-((1-phenylethyl)amino)-6-(1H- pyrazolo[3,4-b]pyr...)
Affinity DataIC50: 200nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Mekanistic Therapeutics

US Patent
LigandPNGBDBM605450(N-(2-chloro-5-(3-cyano-4-((1-(4- fluorophenyl)ethy...)
Affinity DataIC50: 200nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

LigandPNGBDBM605445((R)-6-(2-aminopyrimidin-5-yl)-4-((1- phenylethyl)a...)
Affinity DataIC50: 200nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

LigandPNGBDBM605444(6-(2-aminopyrimidin-5-yl)-4-((1- phenylethyl)amino...)
Affinity DataIC50: 200nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Mekanistic Therapeutics

US Patent
LigandPNGBDBM605443(N-(2-chloro-5-(3-cyano-4-((1S- phenylethyl)amino)q...)
Affinity DataIC50: 200nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Mekanistic Therapeutics

US Patent
LigandPNGBDBM605452(N-(2-chloro-5-(4-((1S-(4- fluorophenyl)ethyl)amino...)
Affinity DataIC50: 200nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Mekanistic Therapeutics

US Patent
LigandPNGBDBM605441(6-(5,6-dimethoxypyridin-3-yl)-N-(1- phenylethyl)qu...)
Affinity DataIC50: 200nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

LigandPNGBDBM605453(6-(2-aminopyrimidin-5-yl)-N-(1-(4- fluorophenyl)et...)
Affinity DataIC50: 200nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

TargetDNA-dependent protein kinase catalytic subunit(Human)
Mekanistic Therapeutics

US Patent
LigandPNGBDBM605453(6-(2-aminopyrimidin-5-yl)-N-(1-(4- fluorophenyl)et...)
Affinity DataIC50: 200nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Mekanistic Therapeutics

US Patent
LigandPNGBDBM605440(N-(2-chloro-5-(4-((1S- phenylethyl)amino)quinazoli...)
Affinity DataIC50: 200nMAssay Description:Z′-LYTE Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seria...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2023
Entry Details
Go to US Patent